New RNA drug aims to stop debilitating swelling attacks in rare genetic condition

NCT ID NCT06960213

Recruiting now Disease control Sponsor: ADARx Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing an experimental drug called ADX-324 in 90 adults with hereditary angioedema (HAE) types 1 or 2. HAE causes sudden, painful swelling in the body. ADX-324 uses a technology called siRNA to lower levels of a protein involved in triggering these attacks. The study compares two doses of ADX-324 against a placebo to see if it can reduce the number of swelling attacks over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

ADX-324 (a type of RNA drug called siRNA that targets a protein involved in swelling attacks)

What this could lead to

If successful, ADX-324 could offer a new way to prevent painful and dangerous swelling attacks in people with hereditary angioedema, reducing attack frequency and improving quality of life.

What could go wrong

This is a phase 3 trial, but it's still relatively small (90 participants). The drug may not work better than placebo, or side effects could emerge. Long-term safety and effectiveness are not yet known.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hereditary angioedema hereditary angioedema type 1 hereditary angioedema type 2

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HAE HEREDITARY ANGIOEDEMA HEREDITARY ANGIOEDEMA - TYPE 1 HEREDITARY ANGIOEDEMA - TYPE 2

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

ADARx Clinical Site
RECRUITING

Litchfield Park, Arizona, 85340, United States
ADARx Clinical Site
RECRUITING

Little Rock, Arkansas, 72205, United States
ADARx Clinical Site
RECRUITING

San Diego, California, 92122, United States
ADARx Clinical Site
RECRUITING

Walnut Creek, California, 94598, United States
ADARx Clinical Site
RECRUITING

Orlando, Florida, 32807, United States
ADARx Clinical Site
RECRUITING

Chevy Chase, Maryland, 20815, United States
ADARx Clinical Site
RECRUITING

Wheaton, Maryland, 20902, United States
ADARx Clinical Site
RECRUITING

Detroit, Michigan, 48202, United States
ADARx Clinical Site
RECRUITING

St Louis, Missouri, 63141, United States
ADARx Clinical Site
RECRUITING

Las Vegas, Nevada, 89128, United States
ADARx Clinical Site
RECRUITING

New York, New York, 10029, United States
ADARx Clinical Site
RECRUITING

Cincinnati, Ohio, 45236, United States
ADARx Clinical Site
RECRUITING

Columbus, Ohio, 43235, United States
ADARx Clinical Site
RECRUITING

Toledo, Ohio, 43617, United States
ADARx Clinical Site
RECRUITING

Hershey, Pennsylvania, 17033, United States
ADARx Clinical Site
NOT_YET_RECRUITING

Capital Federal, Buenos Aires, C1425BEN, Argentina
ADARx Clinical Site
RECRUITING

Buenos Aires, Buenos Aires F.D., C1035AAT, Argentina
ADARx Clinical Site
RECRUITING

Adelaide, South Australia, 5000, Australia
ADARx Clinical Site
RECRUITING

Vienna, 1090, Austria
ADARx Clinical Site
NOT_YET_RECRUITING

Edegem, Antwerpen, 2650, Belgium
ADARx Clinical Site
RECRUITING

Sofia, 1000, Bulgaria
ADARx Clinical Site
NOT_YET_RECRUITING

Edmonton, Alberta, T6G 2R3, Canada
ADARx Clinical Site
RECRUITING

Ottawa, Ontario, K1H 1E4, Canada
ADARx Clinical Site
NOT_YET_RECRUITING

Montreal, Quebec, H2W 1R7, Canada
ADARx Clinical Site
RECRUITING

Beijing, 100730, China
ADARx Clinical Site
NOT_YET_RECRUITING

Harbin, 150001, China
ADARx Clinical Site
NOT_YET_RECRUITING

Zhengzhou, 450003, China
ADARx Clinical Site
RECRUITING

Split, 21000, Croatia
ADARx Clinical Site
RECRUITING

Zagreb, 10000, Croatia
ADARx Clinical Site
RECRUITING

Hradec Králové, 500 05, Czechia
ADARx Clinical Site
RECRUITING

Prague, 15000, Czechia
ADARx Clinical Site
NOT_YET_RECRUITING

Nice, Alpes-Maritimes, 06300, France
ADARx Clinical Site
RECRUITING

Tours, Indre-et-Loire, 37000, France
ADARx Clinical Site
NOT_YET_RECRUITING

Montpellier, 34295, France
ADARx Clinical Site
RECRUITING

Paris, 75012, France
ADARx Clinical Site
RECRUITING

Tübingen, Baden-Wurttemberg, 72076, Germany
ADARx Clinical Site
NOT_YET_RECRUITING

Hong Kong, 111, Hong Kong
ADARx Clinical Site
RECRUITING

Budapest, 1088, Hungary
ADARx Clinical Site
NOT_YET_RECRUITING

Ramat Gan, Tel Aviv, 5262100, Israel
ADARx Clinical Site
NOT_YET_RECRUITING

Ashkelon, 7830604, Israel
ADARx Clinical Site
NOT_YET_RECRUITING

Tel Aviv, 64239, Israel
ADARx Clinical Site
RECRUITING

Krakow, Poland
ADARx Clinical Site
RECRUITING

Lodz, 92-213, Poland
ADARx Clinical Site
RECRUITING

Wroclaw, 50-556, Poland
ADARx Clinical Site
RECRUITING

Barcelona, 08907, Spain
ADARx Clinical Site
RECRUITING

Madrid, 28007, Spain
ADARx Clinical Site
RECRUITING

Taichung, 40705, Taiwan
ADARx Clinical Site
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
ADARx Clinical Site
RECRUITING

Cardiff, CF14 4YS, United Kingdom
ADARx Clinical Site
RECRUITING

London, E1 1BB, United Kingdom
ADARx Clinical Site
RECRUITING

Southampton, SO16 6YD, United Kingdom